4-[4-(2-hydroxy-ethyl)-piperazine-1-carbonyl]-3,5-dimethyl-1H-pyrrole-2-carbaldehyde | 775322-32-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 4-[4-(2-hydroxy-ethyl)-piperazine-1-carbonyl]-3,5-dimethyl-1H-pyrrole-2-carbaldehyde
• 英文别名: 4-[4-(2-hydroxyethyl)piperazine-1-carbonyl]-3,5-dimethyl-1H-pyrrole-2-carbaldehyde
• CAS: 775322-32-2
• 化学式: C₁₄H₂₁N₃O₃
• 分子量: 279.339
• InChiKey: OCBPDHAXJUDMHR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  76.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-[4-(2-hydroxy-ethyl)-piperazine-1-carbonyl]-3,5-dimethyl-1H-pyrrole-2-carbaldehyde 、 5-氟吲哚-2-酮 在 四氢吡咯 作用下， 以 乙醇 为溶剂， 反应 3.0h， 以85%的产率得到(Z)-5-fluoro-3-((4-(4-(2-hydroxyethyl)piperazine-1-carbonyl)-3,5-dimethyl-1H-pyrrol-2-yl)methylene)indolin-2-one
  参考文献：
  名称：

  Synthesis and in vivo SAR study of indolin-2-one-based multi-targeted inhibitors as potential anticancer agents

  摘要：

  A series of indolin-2-one analogues were designed and synthesized, and all of them exhibited excellent in vitro potency. The structure and in vivo activity or toxicity relationship (in-vivo SAR) investigation of indolin-2-one structural analogues was carried out. In vivo efficacy studies indicated that 3b significantly suppressed tumor growth in HT-29 and NCI-H460 xenografts without causing significant loss of body weight. Kinase assay showed that compound 3b effectively inhibited the VEGFR-2, VEGFR-3, FLT3, Ret and PDGFR-beta kinases, but had little effect on the VEGFR-1 kinase. Besides, 3b showed higher selectivity for VEGFR-2 compared with PDGFR-beta. On the basis of its selectivity and safety properties, 3b was identified as a drug candidate for the treatment of cancer. (C) 2014 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2014.05.051
• 作为产物：
  描述：

  N-羟乙基哌嗪 、 2,4-二甲基-5-醛基-1H-吡咯-3-羧酸 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以66%的产率得到4-[4-(2-hydroxy-ethyl)-piperazine-1-carbonyl]-3,5-dimethyl-1H-pyrrole-2-carbaldehyde
  参考文献：
  名称：

  潜在的抗肿瘤药2-吲哚啉酮衍生物的合成及生物学评价

  摘要：

  已经合成了三个系列的3-取代的吲哚啉-2-酮和氮杂吲哚-2-酮，它们显示出对癌细胞系潜在的抗增殖活性。对于选定的2-吲哚满酮，观察到了对VEGF诱导的VEGFR磷酸化的抑制活性。在合成的化合物中，具有吡啶酮单元的5-氟吲哚-2-酮衍生物23显示出最显着的酶和细胞活性。流式细胞仪分析表明23在剂量依赖性的G1期阻滞和凋亡中起着抑制HCT-116细胞增殖的作用。化合物23的结合方式使用FlexX算法预测与VEGFR-2复合。这里描述的是这些系列的化学和生物学测试，它们将指导新型2-吲哚酮抗肿瘤剂的设计和优化。

  DOI：

  10.1016/j.ejmech.2011.10.009

文献信息

• 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors
  申请人：SUGEN Inc.

  公开号：US20040204407A1

  公开（公告）日：2004-10-14

  The present invention relates to 5-sulfonamido substituted indolinones that modulate the activity of protein kinases (“PKs”). The compounds of this invention are therefore useful in treating disorders related to abnormal PK activity. Pharmaceutical compositions comprising these compounds, methods of treating diseases utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.

  本发明涉及调节蛋白激酶（“PKs”）活性的5-磺胺基取代吲哚酮。因此，本发明的化合物在治疗与异常PK活性相关的疾病方面是有用的。包括这些化合物的药物组合物、利用包括这些化合物的药物组合物治疗疾病的方法以及它们的制备方法也被披露。
• Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK)
  申请人：Sugen, Inc.

  公开号：US20040266843A1

  公开（公告）日：2004-12-30

  The present invention relates generally to the field of radiosensitizing agents which are capable of enhancing radiotherapy by inhibiting DNA-PK (DNA-protein kinase). In particular, it relates to sulfonamide substituted indolinones which inhibit DNA-PK.

  本发明通常涉及放射增敏剂领域，这些放射增敏剂能够通过抑制DNA-PK（DNA-蛋白激酶）来增强放射疗法。具体而言，涉及抑制DNA-PK的磺胺基取代吲哚酮。
• Synthesis and biological evaluation of 2-indolinone derivatives as potential antitumor agents
  作者：Hongbin Zou、Liang Zhang、Jingfeng Ouyang、Marc A. Giulianotti、Yongping Yu

  DOI：10.1016/j.ejmech.2011.10.009

  日期：2011.12

  3-substituted-indolin-2-ones and azaindolin-2-ones have been synthesized and showed potential antiproliferative activity to cancer cell lines. The inhibition activities on VEGF-induced VEGFR phosphorylation were observed for selected 2-indolinones. Among the compounds synthesized, 5-fluoroindolin-2-one derivative 23 with a pyridone unit showed the most significant enzymatic and cellular activities. Flow cytometric

  已经合成了三个系列的3-取代的吲哚啉-2-酮和氮杂吲哚-2-酮，它们显示出对癌细胞系潜在的抗增殖活性。对于选定的2-吲哚满酮，观察到了对VEGF诱导的VEGFR磷酸化的抑制活性。在合成的化合物中，具有吡啶酮单元的5-氟吲哚-2-酮衍生物23显示出最显着的酶和细胞活性。流式细胞仪分析表明23在剂量依赖性的G1期阻滞和凋亡中起着抑制HCT-116细胞增殖的作用。化合物23的结合方式使用FlexX算法预测与VEGFR-2复合。这里描述的是这些系列的化学和生物学测试，它们将指导新型2-吲哚酮抗肿瘤剂的设计和优化。
• US7157577B2
  申请人：——

  公开号：US7157577B2

  公开（公告）日：2007-01-02
• Synthesis and in vivo SAR study of indolin-2-one-based multi-targeted inhibitors as potential anticancer agents
  作者：Long Zhang、Qingmei Zheng、Yingying Yang、Haojie Zhou、Xingjiang Gong、Shuyong Zhao、Chuanwen Fan

  DOI：10.1016/j.ejmech.2014.05.051

  日期：2014.7

  A series of indolin-2-one analogues were designed and synthesized, and all of them exhibited excellent in vitro potency. The structure and in vivo activity or toxicity relationship (in-vivo SAR) investigation of indolin-2-one structural analogues was carried out. In vivo efficacy studies indicated that 3b significantly suppressed tumor growth in HT-29 and NCI-H460 xenografts without causing significant loss of body weight. Kinase assay showed that compound 3b effectively inhibited the VEGFR-2, VEGFR-3, FLT3, Ret and PDGFR-beta kinases, but had little effect on the VEGFR-1 kinase. Besides, 3b showed higher selectivity for VEGFR-2 compared with PDGFR-beta. On the basis of its selectivity and safety properties, 3b was identified as a drug candidate for the treatment of cancer. (C) 2014 Elsevier Masson SAS. All rights reserved.